Patents by Inventor Ana Carrizosa Anderson

Ana Carrizosa Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11186825
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 30, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Patent number: 11180730
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 23, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20210130438
    Abstract: The present invention provides novel pan-cancer T cell exhaustion regulators. CXCR6 expressed in CD8+ T cells was specifically identified as regulating anti-tumor immunity. Modulating CXCR6-CXCL16 interaction is useful in modulating anti-tumor immunity. The identified genes may be modulated in T cells for use in adoptive cell transfer. The identified genes may be modulated in vivo.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 6, 2021
    Inventors: Livnat Jerby-Arnon, Ana Carrizosa Anderson, Aviv Regev, Katherine Tooley, Vijay K. Kuchroo
  • Publication number: 20210130776
    Abstract: The subject matter disclosed herein is generally directed to a novel CD8+ T cell subtype associated with suppressive or regulatory T cell functions. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtype. Also, disclosed herein are gene signatures and markers associated with the subtype and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtype. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs depleted for a specific subtype. Further disclosed are interactions with other T cell subtypes.
    Type: Application
    Filed: October 1, 2018
    Publication date: May 6, 2021
    Inventors: Ana Carrizosa Anderson, Vijay K. Kuchroo, Meromit Singer, Aviv Regev
  • Publication number: 20210102168
    Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Publication number: 20210100774
    Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 8, 2021
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20210047694
    Abstract: The present invention is generally directed to a colorectal (CRC) cell atlas that provides methods of predicting outcomes of cancer patients and therapeutic targets for treating patients in need thereof. The atlas may be used to predict a response to immunotherapy, in particular checkpoint blockade therapy and adoptive cell transfer. Disclosed herein are previously unidentified gene programs in tumors that can be used to predict response and provide for therapeutic targets that can be used to shift a tumor to a responsive phenotype.
    Type: Application
    Filed: August 17, 2020
    Publication date: February 18, 2021
    Inventors: Aviv Regev, Nir Hacohen, Vijay K. Kuchroo, Ana Carrizosa Anderson, Orit Rozenblatt-Rosen, Jonathan Chen, Karin Pelka, Matan Hofree
  • Patent number: 10822587
    Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: November 3, 2020
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Vijay Kuchroo, Hongkun Park, Nir Yosef, Alexander K. Shalek, Jellert Gaublomme, Nicole C. Joller, Chuan Wu, Ana Carrizosa Anderson
  • Publication number: 20200102386
    Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.
    Type: Application
    Filed: June 14, 2018
    Publication date: April 2, 2020
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Ayshwarya Subramanian, Orit Rozenblatt-Rosen
  • Publication number: 20200023007
    Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.
    Type: Application
    Filed: June 14, 2019
    Publication date: January 23, 2020
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Ayshwarya Subramanian, Orit Rozenblatt-Rosen
  • Publication number: 20200016202
    Abstract: Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network and novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module.
    Type: Application
    Filed: October 6, 2017
    Publication date: January 16, 2020
    Applicants: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. KUCHROO, Ana Carrizosa ANDERSON, Asaf MADI, Norio CHIHARA, Aviv REGEV, Meromit SINGER, Huiyuan ZHANG
  • Publication number: 20190365781
    Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Application
    Filed: April 26, 2019
    Publication date: December 5, 2019
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20190106679
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 11, 2019
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20190106678
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 11, 2019
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20190100801
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 4, 2019
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20170058026
    Abstract: Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.
    Type: Application
    Filed: October 31, 2016
    Publication date: March 2, 2017
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. Kuchroo, Chen Zhu, Ana Carrizosa Anderson
  • Publication number: 20150361396
    Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.
    Type: Application
    Filed: August 27, 2015
    Publication date: December 17, 2015
    Inventors: Aviv Regev, Vijay Kuchroo, Hongkun Park, Nir Yosef, Alexander K. Shalek, Jellert Gaublomme, Nicole C. Joller, Chuan Wu, Ana Carrizosa Anderson
  • Publication number: 20150284459
    Abstract: Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i.e., inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 8, 2015
    Inventors: Vijay K. Kuchroo, Chen Zhu, Ana Carrizosa Anderson
  • Publication number: 20110059106
    Abstract: The invention provides for methods of modulating a population of myeloid-derived suppressor cells (MDSCs) in a subject, for treating an autoimmune disease, and also treating cancer in a subject in need thereof. The methods comprise administering to the subject a therapeutically effective amount of an agent that modulates the Tim-3 pathway. The Tim-3 pathway can be activated by a Tim-3 ligand, galectin-9, whereby MDSCs are expanded, or inhibited by an antibody to Tim-3, wherein the expansion of MDSCs is inhibited.
    Type: Application
    Filed: January 29, 2009
    Publication date: March 10, 2011
    Applicant: BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Ana Carrizosa Anderson, Valerie Dardalhon